EyePoint (EYPT) stock crashed Monday, undercutting the lower boundary of a cup base, after its eye disease treatment missed the mark in a final-phase study. The company tested its drug, Duravyu, in patients with wet age-related macular degeneration. Though it lowered treatment burden by 42% and 56% of patients were free of supplements by Week 56, the primary goal of…
Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8